Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
481.17M | 423.24M | 270.26M | 220.18M | 38.54M | 0.00 | Gross Profit |
389.86M | 362.33M | 213.74M | 173.21M | 29.44M | -3.81M | EBIT |
-15.80M | -45.62M | -25.20M | 7.37M | -156.64M | -157.36M | EBITDA |
-14.97M | -45.62M | -22.86M | 9.77M | -154.28M | -152.42M | Net Income Common Stockholders |
-16.95M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
268.34M | 243.63M | 206.37M | 190.61M | 182.20M | 323.48M | Total Assets |
599.33M | 580.55M | 526.32M | 459.67M | 232.80M | 349.46M | Total Debt |
9.91M | 9.86M | 12.26M | 5.92M | 6.05M | 6.99M | Net Debt |
-147.22M | -173.73M | -95.70M | -116.80M | -116.42M | -107.05M | Total Liabilities |
141.84M | 142.12M | 87.48M | 63.52M | 47.76M | 37.53M | Stockholders Equity |
457.49M | 438.44M | 438.84M | -492.03M | -675.40M | -517.47M |
Cash Flow | Free Cash Flow | ||||
43.73M | 25.41M | 13.17M | 5.70M | -146.71M | -136.81M | Operating Cash Flow |
44.03M | 25.69M | 13.30M | 5.81M | -126.30M | -136.53M | Investing Cash Flow |
-39.39M | 37.67M | -29.56M | -8.08M | 128.63M | -23.44M | Financing Cash Flow |
11.42M | 12.27M | 1.50M | 2.52M | 5.88M | 227.09M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $2.04B | ― | -3.81% | ― | 59.45% | -290.38% | |
66 Neutral | $2.25B | ― | 18.68% | ― | 41.67% | 75.79% | |
62 Neutral | $1.41B | 66.46 | 1.73% | ― | 3.00% | ― | |
53 Neutral | $5.23B | 3.23 | -44.27% | 2.82% | 16.82% | 0.11% | |
53 Neutral | $1.93B | 21.22 | -6.25% | ― | ― | ― | |
48 Neutral | $1.18B | 64.45 | -10.45% | ― | 24.76% | -783.38% | |
39 Underperform | $2.02B | ― | -39.49% | ― | ― | -20.03% |
On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders where several proposals were voted on and passed. Key decisions included the re-election of directors across three classes, the appointment and remuneration of auditors, and the approval of various financial and governance measures. These resolutions are likely to impact the company’s governance structure and financial operations, potentially influencing its strategic direction and stakeholder relationships.
The most recent analyst rating on (KNSA) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.
On April 17, 2025, Kiniksa Pharmaceuticals‘ Board of Directors approved a Long-Term Incentive Plan for its executive officers, aimed at achieving key milestones related to the development and FDA approval of KPL-387 for recurrent pericarditis. The plan includes cash awards, performance share units, and share options, with the potential for varying earnout percentages based on milestone achievement dates. This initiative reflects Kiniksa’s strategic focus on advancing KPL-387 and incentivizing its leadership to drive the company’s growth and market positioning.